MindSpire, the neurotech start-up dedicated to helping people regulate stress and unlock peak performance, has raised £850,000 in pre-seed funding. This investment will support the launch of MindSpire’s first device: SONA™, a medical-grade wearable that delivers precision-coded electrical pulses to the vagus nerve, activating brain circuits for calm, focus and enhanced learning.

The round was led by SFC Capital, with participation from SyndicateRoom and non-dilutive innovation funding secured via Innovate UK’s Investor Partnership Programme. The £850,000 investment will enable MindSpire, based at the London Institute for Healthcare Engineering (LIHE), to complete the development and launch of SONA™.

MindSpire exists to make advanced nervous system care not only effective for high performers but also meaningful for those who need it most. Early sales of SONA™ will continue to fund research into how the technology can relieve chronic stress in people facing real-world challenges such as anxiety, long COVID, trauma, burnout and frontline fatigue.

MindSpire was founded to address the impact of chronic stress on health. The start-up’s AI-driven platform combines vagus nerve stimulation with real-time personalisation to enhance cognitive function and emotional regulation, enabling users to optimise their mental states and improve focus, learning and resilience.

“Our goal is to create a solution that performs just as well for executives managing stress and recovery as it does for individuals rebuilding from chronic conditions. It reflects our commitment to making nervous system care accessible, especially for those who need it most” – Jane Ollis, Founder and CEO of MindSpire.

“MindSpire is leading the way in integrating adaptive AI with cutting-edge neuroscience. What excites me is the potential to deliver real-time, personalised interventions that respond to the body’s signals. It is a true fusion of intelligence and biology that could redefine how we manage stress and performance.” – Dr. Amir Konigsberg, Chair of MindSpire and expert in artificial intelligence.

“We’re delighted to invest in MindSpire and enable them complete the development and launch of SONA™. We look forward to the impact they make in treating chronic stress and anxiety, and to welcome another promising company at the cross section of AI and cutting edge healthtech to the Access EIS portfolio.” – Tom Britton, Founding Partner, SyndicateRoom

“MindSpire’s technology represents a shift in how we approach mental performance and resilience. We are excited to support their innovative solutions and look forward to seeing their impact on the market.” – Adam Beveridge, Investment Executive at SFC Capital.

MindSpire’s breakthrough lies in the precision and personalisation of its stimulation. SONA™ delivers biologically-aligned electrical pulses from the outer ear to the brainstem, syncing with the brain’s natural rhythms. This is achieved through vagus nerve stimulation (taVNS), real-time HRV (Heart Rate Variability) sensing and sound. These precision-coded inputs rebalance autonomic tone, enhance neuroplasticity and support brain performance. Its companion platform, NeuroSphere™, uses AI to personalise stimulation based on each user’s data and goals. It is also supported by early clinical studies for the treatment of stress, tinnitus, Parkinson’s Disease and chronic pain.

“At LIHE, we champion innovators who are redefining precision in healthcare through impactful medical devices. MindSpire’s fusion of non-invasive neurotechnology and adaptive AI represents a bold leap forward in the future of brain health.” – Nicolas Huber, COO, London Institute for Healthcare Engineering.

MindSpire is now actively building strategic partnerships with health platforms and innovators in stress, sleep, longevity and performance. The team is also speaking with investors ahead of its next funding round.

To explore partnership opportunities or join MindSpire’s mission to make stress regulation accessible to everyone, from high performers to those living with chronic stress, get in touch via jane.ollis@mindspire.co.uk.

Follow MindSpire on LinkedIn for early updates on the SONA™ launch, to join the beta community and to be part of a movement that helps people achieve peak performance.